Beecher Falls Clinic Llc | |
106 River Road Beecher Falls VT 05902 | |
(603) 237-8482 | |
Not Available |
Full Name | Beecher Falls Clinic Llc |
---|---|
Speciality | Internal Medicine |
Location | 106 River Road, Beecher Falls, Vermont |
Authorized Official Name and Position | Clifford A Chapin (CHIEF EXECUTIVE MANAGER AGENT) |
Authorized Official Contact | 6032378482 |
Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
Mailing Address | Practice Location Address |
---|---|
Beecher Falls Clinic Llc 106 River Road Beecher Falls VT 05902 Ph: (603) 237-8482 | Beecher Falls Clinic Llc 106 River Road Beecher Falls VT 05902 Ph: (603) 237-8482 |
NPI Number | 1134398100 |
---|---|
Provider Enumeration Date | 02/25/2008 |
Last Update Date | 02/25/2008 |
Identifier | Type | State | Issuer |
---|---|---|---|
1134398100 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207R00000X | Internal Medicine | 12369 (New Hampshire) | Primary |
News Archive
An initiative by the British Government to encourage more respect for older people in care has been given added impact by the recruitment of TV talk show host Sir Michael Parkinson as a "dignity ambassador".
Biomedical engineering researchers at North Carolina State University and the University of North Carolina at Chapel Hill have developed a technique that uses a patch embedded with microneedles to deliver cancer immunotherapy treatment directly to the site of melanoma skin cancer. In animal studies, the technique more effectively targeted melanoma than other immunotherapy treatments.
New research from The University of Texas Health Science Center at Houston School of Public Health, released Tuesday in Alcoholism: Clinical & Experimental Research, shows that higher levels of drinking among United States-Mexico border young adults are closely linked to their patterns of bar attendance, but not to how they think about drinking.
Northrop Grumman Corporation will highlight technology and solutions applicable to the military, public health entities, and the state and local market next week at the Healthcare Information and Management Systems Society (HIMSS) 2011 Annual Conference and Exposition.
Biodel, Inc. announced today that its chief executive officer, Dr. Sol Steiner, will present results from the company's two Phase 3 studies with VIAject® ultra-rapid-acting recombinant human insulin in a platform presentation at the 3rd International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland, on Friday, February 12, 2010, at 1pm central European time.
› Verified 5 days ago